![]() |
|
|
Vol. 286, Issue 2, 931-937, August 1998
Section of Medical Sciences, Department of Biomedical and
Therapeutic Sciences, University of Illinois College of Medicine at
Peoria, Peoria, Illinois (J.E.N., R.G.F., R.J.W.) and
Laboratory of
Medicinal Chemistry, NIDDK, NIH, Bethesda, Maryland (S.N.C., K.C.R.)
We investigated the effects of (+)-4-[(
R)-
-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80), a nonpeptidic delta-opioid receptor-selective
agonist, on rat leukocyte functions. Intracerebroventricular injection of SNC 80 (20 nmol) in Fischer 344N male rats did not affect splenic natural killer cell activity compared with intracerebroventricular saline-injected controls. SNC 80 also had no effect on concanavalin A-,
anti-T cell receptor-, interleukin-2- and anti-T cell receptor + interleukin-2-induced splenic and thymic lymphocyte proliferation in
most experiments. In some experiments, however, SNC 80 significantly (P < .01) caused a 41 to 93% increase of concanavalin A-, anti-T cell receptor-, interleukin-2- and anti-T cell receptor + interleukin-2-induced splenic lymphocyte proliferation compared to
controls. Additionally, SNC 80 did not significantly affect splenic T
cell or natural killer cell populations as measured by the expression
of T cell receptor
, and T helper (CD4), T
suppressor/cytotoxic (CD8) and natural killer cell surface markers.
Finally, SNC 80 did not affect interferon-
- or lipopolysaccharide
(LPS)-induced splenic nitric oxide, and LPS-induced tumor necrosis
factor-
production by splenic macrophages. These results suggest
that SNC 80 could be useful in the treatment of pain without
suppressing immune function. However, the potential immunoenhancing
properties of SNC 80 may be also valuable in immunocompromised
individuals.